Serum Levels of FABP4 and Fetuin-A as Potential Biomarkers in Thyroid Diseases: A Comparative Study

Burhan Talip Lafta; Suhad Hassan Aubaid; Ekhlas Saddam Falih

doi:10.54133/ajms.v8i2(Special).1362

Authors

Burhan Talip Lafta Baghdad Karkh Health Directorate, Iraqi Ministry of Health, Baghdad, Iraq https://orcid.org/0009-0003-3496-7447
Suhad Hassan Aubaid Department of Medical Laboratory Techniques, College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq https://orcid.org/0000-0002-6170-6619
Ekhlas Saddam Falih Department of Medical Laboratory Techniques, College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.54133/ajms.v8i2(Special).1362

Keywords:

Fatty acid-binding protein, Fetuin-A, Thyroid disease

Abstract

Background: Fatty acid-binding protein 4 (FABP4) moves lipids inside cells. Fetuin-A is a liver-derived glycoprotein that prevents vascular calcification. Recent studies link higher serum levels of both proteins to metabolic syndrome, suggesting a risk for metabolic issues. Objectives: To explore the roles of FABP4 and Fetuin-A as biomarkers in thyroid diseases. The outcomes of this research have important ramifications for both prevention and treatment methods. Approach: Methods: For this specific research, a case-control study methodology was employed, comprising a newly diagnosed 120 thyroid disease patients. 30 healthy controls were age- and gender-matched to these patients. Using the enzyme-linked immunosorbent assay (ELISA) method, fetuin-A and FABP4 concentrations were assessed. Results: Individuals with thyroid diseases showed significantly elevated levels of both biomarkers compared to the healthy control group (p<0.001). This observation was significant in terms of its sensitivity and specificity. Additionally, a solid correlation between FABP4 and fetuin-A was found, with a correlation coefficient of r=0.8199 and a significance of p=0.000. Conclusions: Based on these findings, FABP4 and fetuin-A may be crucial in metabolic irregularities linked to thyroid dysfunction.

Downloads

Download data is not yet available.

References

Volke L, Krause K. Effect of thyroid hormones on adipose tissue flexibility. Eur Thyroid J. 2021;10(1):1–9. doi: 10.1159/000508483. DOI: https://doi.org/10.1159/000508483

Taha KN, Risan FA, Mohammed AJ. Possible roles of micro RNA 142 5p and claudin-1 in development of Hashimoto’s thyroiditis in Iraqi patients. J Techniques. 2022;4(2):50–55. doi: 10.51173/jt.v4i2.473. DOI: https://doi.org/10.51173/jt.v4i2.473

Li HL, Wu X, Xu A, Hoo RL. A-FABP in metabolic diseases and the therapeutic implications: An update. Int J Mol Sci. 2021;22(17):9386. doi: 10.3390/ijms22179386. DOI: https://doi.org/10.3390/ijms22179386

Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18(8):1279-1285. doi: 10.1038/nm.2851. DOI: https://doi.org/10.1038/nm.2851

Zybek-Kocik A, Sawicka-Gutaj N, Domin R, Szczepanek-Parulska E, Krauze T, Guzik P, et al. Titin and dystrophin serum concentration changes in patients affected by thyroid disorders. Endokrynol Pol. 2021;72(1):1-7. doi: 10.5603/EP.a2020.0083. DOI: https://doi.org/10.5603/EP.a2020.0083

García-Solís P, García OP, Hernández-Puga G, Sánchez-Tusie AA, Sáenz-Luna CE, Hernández-Montiel HL, et al. Thyroid hormones and obesity: a known but poorly understood relationship. Endokrynol Pol. 2018;69(3):292-303. doi: 10.5603/EP.2018.0032. DOI: https://doi.org/10.5603/EP.2018.0032

Sabri NW, Rashid BA, Shwiehk RS, Mahdy AH. Assessment of Risk Factors of Chronic Kidney Disease among Patients Attending Medical City Complex. J Techniques. 2023;5(2):147–154. doi: 10.51173/jt.v5i2.885. DOI: https://doi.org/10.51173/jt.v5i2.885

Pala L, Monami M, Ciani S, Dicembrini I, Pasqua A, Pezzatini A, et al. Adipokines as possible new predictors of cardiovascular diseases: a case control study. J Nutr Metab. 2012;2012:253428. doi: 10.1155/2012/253428. DOI: https://doi.org/10.1155/2012/253428

Alkharfy KM, Al-Daghri NM, Vanhoutte PM, Krishnaswamy S, Xu A. Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS One. 2012;7(10):e48612. doi: 10.1371/journal.pone.0048612. DOI: https://doi.org/10.1371/journal.pone.0048612

Fan J, Yin S, Lin D, Liu Y, Chen N, Bai X, et al. Association of serum retinol-binding protein 4 levels and the risk of incident type 2 diabetes in subjects with prediabetes. Diabetes Care. 2019;42(8):1574-1581. doi: 10.2337/dc19-0265. DOI: https://doi.org/10.2337/dc19-0265

Mohammed SN, Jassim WE, Mohammed NA. To investigate the associations of dyslipidemia and BMI, as risk factors leading to insulin resistance and development of type2 diabetes mellitus in Baquba city. J Techniques. 2022;4(3):27–33. doi: 10.51173/jt.v4i3.538. DOI: https://doi.org/10.51173/jt.v4i3.538

Dadej D, Szczepanek-Parulska E, Ruchała M. Interplay between fatty acid binding protein 4, fetuin-A, retinol binding protein 4 and thyroid function in metabolic dysregulation. Metabolites. 2022;12(4):300. doi: 10.3390/metabo12040300. DOI: https://doi.org/10.3390/metabo12040300

Aleksandrova K, Drogan D, Weikert C, Schulze MB, Fritsche A, Boeing H, et al. Fatty acid-binding protein 4 and risk of type 2 diabetes, myocardial infarction, and stroke: A prospective cohort study. J Clin Endocrinol Metab. 2019;104(12):5991-6002. doi: 10.1210/jc.2019-00477. DOI: https://doi.org/10.1210/jc.2019-00477

Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008;57(10):2762-2767. doi: 10.2337/db08-0538. DOI: https://doi.org/10.2337/db08-0538

Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2018;41(1):33-47. doi: 10.1007/s40618-017-0697-8. DOI: https://doi.org/10.1007/s40618-017-0697-8

Pamuk BO, Yilmaz H, Topcuoglu T, Bilgir O, Çalan O, Pamuk G, et al. Fetuin-A levels in hyperthyroidism. Clinics (Sao Paulo). 2013;68(3):379-383. doi: 10.6061/clinics/2013(03)oa15. DOI: https://doi.org/10.6061/clinics/2013(03)OA15

Ammar SR, Elbedewy TA, Nagy HM, Kotb, NA. Relationship between serum Fetuin-A and insulin resistance in patients with hyperthyroidism. Tanta Med J. 2027;45(3):135-140. doi: 10.4103/tmj.tmj_4_17. DOI: https://doi.org/10.4103/tmj.tmj_4_17

Bakiner O, Bozkirli E, Ertugrul D, Sezgin N, Ertorer E. Plasma fetuin-A levels are reduced in patients with hypothyroidism. Eur J Endocrinol. 2014;170(3):411-418. doi: 10.1530/EJE-13-0831. DOI: https://doi.org/10.1530/EJE-13-0831

Icer MA, Yıldıran H. Effects of nutritional status on serum fetuin-A level. Crit Rev Food Sci Nutr. 2020;60(11):1938-1946. doi: 10.1080/10408398.2019.1631751. DOI: https://doi.org/10.1080/10408398.2019.1631751

Brix JM, Stingl H, Höllerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010;95(11):4877-4881. doi: 10.1210/jc.2010-0148. DOI: https://doi.org/10.1210/jc.2010-0148

Seo DY, Park SH, Marquez J, Kwak HB, Kim TN, Bae JH, et al. Hepatokines as a molecular transducer of exercise. J Clin Med. 2021;10(3):385. doi: 10.3390/jcm10030385. DOI: https://doi.org/10.3390/jcm10030385

Afrisham R, Paknejad M, Ilbeigi D, Sadegh-Nejadi S, Gorgani-Firuzjaee S, Vahidi M. Positive correlation between circulating fetuin-A and severity of coronary artery disease in men. Endocr Metab Immune Disord Drug Targets. 2021;21(2):338-344. doi: 10.2174/1871530320666200601164253. DOI: https://doi.org/10.2174/1871530320666200601164253

Birukov A, Polemiti E, Jäger S, Stefan N, Schulze MB. Fetuin-A and risk of diabetes-related vascular complications: a prospective study. Cardiovasc Diabetol. 2022;21(1):6. doi: 10.1186/s12933-021-01439-8. DOI: https://doi.org/10.1186/s12933-021-01439-8

Nimptsch K, Janke J, Pischon T, Linseisen J. Association between dietary factors and plasma fetuin-A concentrations in the general population. Br J Nutr. 2015;114(8):1278-1285. doi: 10.1017/S0007114515002639. DOI: https://doi.org/10.1017/S0007114515002639

Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113(14):1760-1767. doi: 10.1161/CIRCULATIONAHA.105.588723. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.588723

Zachariah JP, Quiroz R, Nelson KP, Teng Z, Keaney JF, Sullivan LM, et al. Prospective relation of circulating adipokines to incident metabolic syndrome: The Framingham Heart Study. J Am Heart Assoc. 2017;6(7):e004974. doi: 10.1161/JAHA.116.004974. DOI: https://doi.org/10.1161/JAHA.116.004974

Pan X, Kaminga AC, Chen J, Luo M, Luo J. Fetuin-A and fetuin-B in non-alcoholic fatty liver disease: A meta-analysis and meta-regression. Int J Environ Res Public Health. 2020;17(8):2735. doi: 10.3390/ijerph17082735. DOI: https://doi.org/10.3390/ijerph17082735

Guo VY, Cao B, Cai C, Cheng KK, Cheung BMY. Fetuin-A levels and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol. 2018;55(1):87-98. doi: 10.1007/s00592-017-1068-9. DOI: https://doi.org/10.1007/s00592-017-1068-9

Egbuche O, Biggs ML, Ix JH, Kizer JR, Lyles MF, Siscovick DS, et al. Fatty Acid binding protein-4 and risk of cardiovascular disease: The Cardiovascular Health Study. J Am Heart Assoc. 2020;9(7):e014070. doi: 10.1161/JAHA.119.014070. DOI: https://doi.org/10.1161/JAHA.119.014070

Sujana C, Huth C, Zierer A, Meesters S, Sudduth-Klinger J, Koenig W, et al. Association of fetuin-A with incident type 2 diabetes: results from the MONICA/KORA Augsburg study and a systematic meta-analysis. Eur J Endocrinol. 2018;178(4):389-398. doi: 10.1530/EJE-17-1053. DOI: https://doi.org/10.1530/EJE-17-1053

Trojnar M, Patro-Małysza J, Kimber-Trojnar Ż, Leszczyńska-Gorzelak B, Mosiewicz J. Associations between fatty acid-binding protein 4: A proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells. 2019;8(3):227. doi: 10.3390/cells8030227. DOI: https://doi.org/10.3390/cells8030227

Lee CH, Lui DTW, Lam KSL. Adipocyte fatty acid-binding protein, cardiovascular diseases and mortality. Front Immunol. 2021;12:589206. doi: 10.3389/fimmu.2021.589206. DOI: https://doi.org/10.3389/fimmu.2021.589206

Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues. Diabetes. 2014;63(3):900-9011. doi: 10.2337/db13-0436. DOI: https://doi.org/10.2337/db13-0436

Furuhashi M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb. 2019;26(3):216-232. doi: 10.5551/jat.48710. DOI: https://doi.org/10.5551/jat.48710

Sun J, Zhang D, Xu J, Chen C, Deng D, Pan F, et al. Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis. Lipids Health Dis. 2020;19(1):199. doi: 10.1186/s12944-020-01365-w. DOI: https://doi.org/10.1186/s12944-020-01365-w

Prentice KJ, Saksi J, Robertson LT, Lee GY, Inouye KE, Eguchi K, et al. A hormone complex of FABP4 and nucleoside kinases regulates islet function. Nature. 2021;600(7890):720-726. doi: 10.1038/s41586-021-04137-3. DOI: https://doi.org/10.1038/s41586-021-04137-3

Nie X, Ma X, Xu Y, Shen Y, Wang Y, Bao Y. Increased serum adipocyte fatty acid-binding protein levels are associated with decreased sensitivity to thyroid hormones in the euthyroid population. Thyroid. 2020;30(12):1718-1723. doi: 10.1089/thy.2020.0011. DOI: https://doi.org/10.1089/thy.2020.0011

Parra S, Cabré A, Marimon F, Ferré R, Ribalta J, Gonzàlez M, et al. Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients. Lupus. 2014;23(3):245-254. doi: 10.1177/0961203313517405. DOI: https://doi.org/10.1177/0961203313517405

Shu L, Hoo RL, Wu X, Pan Y, Lee IP, Cheong LY, et al. A-FABP mediates adaptive thermogenesis by promoting intracellular activation of thyroid hormones in brown adipocytes. Nat Commun. 2017;8:14147. doi: 10.1038/ncomms14147. DOI: https://doi.org/10.1038/ncomms14147